Who are Placebo,Fulvestrant,Goserelin acetate's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-fulvestrant-goserelin-acetate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo,Fulvestrant,Goserelin acetate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo,Fulvestrant,Goserelin acetate (Placebo,Fulvestrant,Goserelin acetate) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor degrader (SERD) + GnRH agonist combination. Area: Oncology.

phase 3 Selective estrogen receptor degrader (SERD) + GnRH agonist combination Estrogen receptor (ER) + GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo,Fulvestrant,Goserelin acetate (Placebo,Fulvestrant,Goserelin acetate) — Ahon Pharmaceutical Co., Ltd.. This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo,Fulvestrant,Goserelin acetate TARGET	Placebo,Fulvestrant,Goserelin acetate	Ahon Pharmaceutical Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + GnRH agonist combination	Estrogen receptor (ER) + GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor degrader (SERD) + GnRH agonist combination class)

Ahon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo,Fulvestrant,Goserelin acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-fulvestrant-goserelin-acetate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab